Alterity Therapeutics (PRAN) Competitors

Cybin (NYSE:CYBN) and Alterity Therapeutics (NASDAQ:PRAN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Do insiders & institutionals have more ownership in CYBN or PRAN?

17.9% of Cybin shares are owned by institutional investors. Comparatively, 3.6% of Alterity Therapeutics shares are owned by institutional investors. 15.0% of Cybin shares are owned by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Does the media refer more to CYBN or PRAN?

In the previous week, Cybin had 17 more articles in the media than Alterity Therapeutics. MarketBeat recorded 18 mentions for Cybin and 1 mentions for Alterity Therapeutics. Cybin's average media sentiment score of 0.01 beat Alterity Therapeutics' score of 0.00 indicating that Cybin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cybin	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alterity Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has better earnings & valuation, CYBN or PRAN?

Alterity Therapeutics has higher revenue and earnings than Cybin. Alterity Therapeutics is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$57.88M	-$4.60	-1.55
Alterity Therapeutics	$150K	297.85	-$6.40M	-$0.70	-7.17

Is CYBN or PRAN more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-37.58%	-36.59%
Alterity Therapeutics	N/A	N/A	N/A

Do analysts prefer CYBN or PRAN?

Cybin currently has a consensus price target of $85.00, indicating a potential upside of 1,088.81%. Given Cybin's stronger consensus rating and higher possible upside, equities analysts clearly believe Cybin is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25
Alterity Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Which has more volatility & risk, CYBN or PRAN?

Cybin has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.

Summary

Cybin beats Alterity Therapeutics on 8 of the 15 factors compared between the two stocks.